West Branch Capital LLC increased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 1.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 53,968 shares of the biopharmaceutical company’s stock after acquiring an additional 830 shares during the period. Pfizer comprises approximately 1.7% of West Branch Capital LLC’s holdings, making the stock its 16th largest position. West Branch Capital LLC’s holdings in Pfizer were worth $2,765,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Front Street Capital Management Inc. lifted its holdings in shares of Pfizer by 4.3% during the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares in the last quarter. Lindenwold Advisors grew its stake in shares of Pfizer by 1.0% during the 3rd quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock valued at $926,000 after purchasing an additional 216 shares during the period. SRS Capital Advisors Inc. increased its position in shares of Pfizer by 1.6% during the 2nd quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock valued at $714,000 after purchasing an additional 218 shares during the last quarter. Signet Financial Management LLC lifted its stake in shares of Pfizer by 0.6% in the 3rd quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock worth $1,503,000 after purchasing an additional 220 shares during the period. Finally, Mitchell Mcleod Pugh & Williams Inc. boosted its holdings in shares of Pfizer by 0.7% in the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock worth $1,487,000 after buying an additional 222 shares during the last quarter. 67.62% of the stock is owned by institutional investors.
Insider Transactions at Pfizer
In related news, major shareholder Pfizer Inc acquired 1,811,594 shares of the firm’s stock in a transaction that occurred on Friday, March 17th. The stock was purchased at an average cost of $2.76 per share, with a total value of $4,999,999.44. Following the transaction, the insider now directly owns 5,952,263 shares of the company’s stock, valued at approximately $16,428,245.88. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.05% of the company’s stock.
Pfizer Price Performance
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The firm had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. During the same quarter last year, the firm earned $1.08 EPS. The business’s quarterly revenue was up 1.9% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research analysts have weighed in on the stock. StockNews.com began coverage on shares of Pfizer in a research report on Thursday, March 16th. They issued a “buy” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 target price on shares of Pfizer in a report on Wednesday, February 1st. SVB Leerink cut their price target on Pfizer from $49.00 to $48.00 and set a “market perform” rating for the company in a report on Wednesday, February 1st. JPMorgan Chase & Co. set a $45.00 price target on Pfizer in a research report on Monday, February 27th. Finally, Barclays cut their price objective on Pfizer from $49.00 to $44.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 1st. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $49.93.
Pfizer Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Recommended Stories
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Novartis Shares Leap On Positive Clinical Trial Data
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
